Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2023

Autores

da Ana, R (Autor) Outra; Gliszczynska, A (Autor) Outra; Sanchez-Lopez, E (Autor) Outra; Garcia, ML (Autor) Outra; Krambeck, K (Autor) Outra; Kovacevic, A (Autor) Outra; Souto, EB (Autor) FFUP

Revista

A Revista está pendente de validação pelos Serviços Administrativos.

Título: JOURNAL OF PERSONALIZED MEDICINE

Vol. 13

Página Final: 635

ISSN: 2075-4426

Editora: MDPI

Indexação

ISI Web of Knowledge - 0 Citações

Scopus

Outras Informações

ID Authenticus: P-00Y-BKT

DOI: 10.3390/jpm13040635

Abstract (EN): Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch's membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 17